On Wednesday, Shares of Perrigo Company plc Ordinary Shares (NYSE:PRGO), added 3.61% and closed at $83.51 in the last trading session. The last trading range of the stock ranges between $80.90 and $87.68. Perrigo Company plc (NYSE: PRGO; TASE) recently declared results for the third quarter ended October 1, 2016.
Perrigo’s CEO John T. Hendrickson commented, “Every segment delivered year-over-year net sales growth, apart from net sales from held-for-sale businesses. The CHC team again delivered a solid quarter with attractive margins. While stated net sales within the U.S. Consumer Healthcare business were flat year-over-year, adjusted net sales grew about 4%. In addition, I am happy with the changes implemented in the Rx segment, where our productivity improvements in the quarter partially offset the effect of the competitive pricing environment. Despite lower margins year-over-year and the impairment realized this quarter, the BCH segment’s net sales were consistent with the prior year. This segment remains a top priority for our team. In addition, our business model continues to deliver strong cash flow conversion, generating $304 million of operating cash flows in the quarter.”
Immune Pharmaceuticals Inc (NASDAQ:IMNP), dropped -4.49% and closed at $0.170 in the last trading session. The last trading range of the stock ranges between $0.16 and $0.18. The company’s Market capitalization is $20.94 Billion with the total Outstanding Shares of 124.79 million. Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas. The companys lead product candidate is Bertilimumab, a human monoclonal antibody, which is in Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn’s disease. It is also developing NanoCyclo, a topical nanocapsule formulation of cyclosporine, for the treatment of psoriasis and atopic dermatitis; Ceplene, a small molecule, which has accomplished Phase III clinical trials targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies; Azixa, a Phase II clinical trial novel microtubular destabilizer that functions as a vascular disruption agent; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is in Phase II clinical trials for the treatment of patients with solid tumors.